A Phase 2 interventional study of LCI699 and Eplerenone in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2008, is one of 3 in phase 2, and was the 9th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 16 · Phase 4 5
First in 2005; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 506 across the 25 interventional studies, 20,984 across the 2 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Essential Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.
Drug: LCI699
Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.
Drug: LCI699
Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.
Drug: LCI699
Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
Drug: LCI699
Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.
Drug: Eplerenone
Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.
Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo
Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699
Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699-matching Placebo
Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699
Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699-matching Placebo
Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699
Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699-matching Placebo
Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699
Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699-matching Placebo
Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
Drug: Eplerenone
Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
Drug: Eplerenone-matching Placebo
Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).
Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo
LCI699 oral capsules
Eplerenone oral capsules
LCI699-matching placebo oral capsules
Eplerenone-matching placebo oral capsules
Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.
Time frame: Baseline, Week 8
Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.
Time frame: Baseline, Week 8
Core Period: Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), and Deaths
An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.
Time frame: AEs: From start of the study drug treatment up to 8 weeks; SAE: From signing of the informed consent up to 8 weeks
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.
Time frame: Baseline, Week 8
Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.
Time frame: Baseline, Week 8
Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM)
An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.
Time frame: Baseline, Week 8
Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM
An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.
Time frame: Baseline, Week 8
Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP at Week 8
Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.
Time frame: Baseline, every hour up to 24 hours post-dose at Week 8
Core Period: Trough to Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP at Week 8
Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.
Time frame: Baseline, every hour up to 24 hours post-dose at Week 8
Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8
Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.
Time frame: Baseline, Week 8
Core Period: Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8 LOCF
MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg.
Time frame: Baseline, Week 8
Core Period: Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8 LOCF
MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg.
Time frame: Baseline, Week 8
Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test
The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.
Time frame: Baseline, 1 hour post-dose at Week 8
Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.
Time frame: From Week 8 to Week 9
Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.
Time frame: From Week 8 to Week 9
Participants took part at 84 investigative sites in Argentina, Australia, France, Germany, Netherlands, Romania, Spain, Sweden, and the United States from 11 September 2008 to 02 July 2009.
| Milestone | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 92 | 88 | 86 | 97 | 84 | 77 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 92 | 87 | 87 | 97 | 84 | 76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 84 | 81 | 77 | 90 | 75 | 67 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 7 | 9 | 7 | 9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 2 | 4 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 2 | 3 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Abnormal test procedure results | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 46 | 38 | 44 | 37 | 41 | 37 | 45 | 45 | 39 | 36 | 66 |
| Randomized withdrawal set | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 38 | 43 | 37 | 41 | 36 | 45 | 44 | 39 | 36 | 67 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 38 | 42 | 37 | 41 | 37 | 45 | 45 | 39 | 36 | 66 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP) | -4.47 ± 0.60 | -5.50 ± 0.57 | -7.11 ± 0.88 | -4.25 ± 0.95 | -7.49 ± 0.97 | -3.22 ± 0.87 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 LOCF, as Measured by OBP | -9.00 ± 1.40 | -10.69 ± 0.98 | -11.93 ± 1.44 | -9.10 ± 1.45 | -13.31 ± 1.48 | -2.93 ± 1.68 |
An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality.
| Participants | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| AEs | 23 | 22 | 24 | 27 | 26 | 23 |
| SAEs | 1 | 0 | 0 | 0 | 0 | 1 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and region as factors and baseline MSDBP level as a covariate.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID |
|---|---|---|---|---|
| Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSDBP at Week 8 | -4.47 ± 0.60 | -5.50 ± 0.57 | -7.11 ± 0.88 | -4.25 ± 0.95 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an ANCOVA with treatment and region as factors and baseline MSSBP levels as a covariate.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID |
|---|---|---|---|---|
| Core Period: Dose Response Relationship of LCI699 as Measured by Change From Baseline in MSSBP at Week 8 | -9.00 ± 1.40 | -10.69 ± 0.98 | -11.93 ± 1.44 | -9.10 ± 1.45 |
An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory SBP readings for the 24-hour period.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Mean 24 Hour Ambulatory SBP at Week 8 as Measured by Ambulatory Blood Pressure Monitoring (ABPM) | -7.15 ± 1.20 | -4.90 ± 1.22 | -7.73 ± 1.13 | -6.18 ± 1.14 | -10.52 ± 1.25 | 1.11 ± 1.30 |
An ABPM measured a participant's BP over a 24-hour period readings using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory DBP readings for the 24-hour period.
| mm Hg | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Mean 24 Hour Ambulatory DBP at Week 8, as Measured by ABPM | -4.03 ± 0.91 | -2.44 ± 0.92 | -4.96 ± 0.86 | -2.75 ± 0.86 | -6.03 ± 0.94 | 1.03 ± 0.99 |
Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.
| ratio | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Week 8, Hour 1 | 3.91 ± 1.466 | 2.95 ± 1.541 | 0.27 ± 1.389 | 3.87 ± 1.404 | 0.17 ± 1.544 | 7.11 ± 1.588 |
| Week 8, Hour 2 | 1.44 ± 1.452 | 1.85 ± 1.488 | 0.17 ± 1.397 | 3.44 ± 1.381 | -1.65 ± 1.529 | 6.28 ± 1.586 |
| Week 8, Hour 3 | 1.16 ± 1.477 | 1.13 ± 1.502 | -0.36 ± 1.387 | 4.01 ± 1.369 | -2.42 ± 1.528 | 4.99 ± 1.585 |
| Week 8, Hour 4 | 0.51 ± 1.452 | 2.91 ± 1.488 | 0.35 ± 1.386 | 2.64 ± 1.378 | -1.39 ± 1.541 | 7.02 ± 1.584 |
| Week 8, Hour 5 | 1.11 ± 1.463 | -0.02 ± 1.513 | -1.69 ± 1.385 | 1.45 ± 1.377 | -2.91 ± 1.514 | 4.31 ± 1.584 |
| Week 8, Hour 6 | -1.18 ± 1.451 | -2.36 ± 1.487 | -3.01 ± 1.386 | 1.20 ± 1.367 | -4.86 ± 1.513 | 1.82 ± 1.585 |
| Week 8, Hour 7 | -1.85 ± 1.463 | -0.95 ± 1.487 | -2.63 ± 1.406 | 1.21 ± 1.366 | -3.70 ± 1.513 | 3.62 ± 1.599 |
| Week 8, Hour 8 | -3.01 ± 1.464 | -1.38 ± 1.487 | -2.43 ± 1.396 | 2.09 ± 1.366 | -2.30 ± 1.514 | 2.65 ± 1.616 |
| Week 8, Hour 9 | -1.24 ± 1.464 | -0.07 ± 1.487 | -2.25 ± 1.386 | 3.27 ± 1.366 | -2.81 ± 1.515 | 3.30 ± 1.600 |
| Week 8, Hour 10 | -0.59 ± 1.452 | 2.60 ± 1.487 | -1.65 ± 1.385 | 0.49 ± 1.378 | -2.43 ± 1.515 | 3.86 ± 1.585 |
| Week 8, Hour 11 | -1.02 ± 1.451 | 1.72 ± 1.487 | -1.54 ± 1.386 | 1.54 ± 1.367 | -1.93 ± 1.514 | 2.38 ± 1.585 |
| Week 8, Hour 12 | -1.60 ± 1.451 | 2.53 ± 1.487 | -3.10 ± 1.385 | -1.06 ± 1.367 | -3.20 ± 1.527 | 3.24 ± 1.584 |
| Week 8, Hour 13 | -4.32 ± 1.451 | -1.20 ± 1.487 | -5.31 ± 1.385 | -1.45 ± 1.366 | -5.35 ± 1.513 | 1.52 ± 1.584 |
| Week 8, Hour 14 | -6.47 ± 1.451 | -3.29 ± 1.487 | -7.38 ± 1.385 | -2.96 ± 1.376 | -7.64 ± 1.513 | -0.90 ± 1.584 |
| Week 8, Hour 15 | -8.34 ± 1.452 | -5.82 ± 1.488 | -8.89 ± 1.386 | -6.10 ± 1.377 | -9.03 ± 1.527 | -1.01 ± 1.586 |
| Week 8, Hour 16 | -8.92 ± 1.465 | -8.37 ± 1.491 | -10.50 ± 1.387 | -9.54 ± 1.369 | -12.55 ± 1.528 | -1.61 ± 1.587 |
| Week 8, Hour 17 | -10.26 ± 1.454 | -10.99 ± 1.492 | -12.71 ± 1.398 | -10.38 ± 1.380 | -12.88 ± 1.516 | -4.20 ± 1.604 |
| Week 8, Hour 18 | -10.68 ± 1.456 | -11.73 ± 1.492 | -11.88 ± 1.389 | -11.85 ± 1.379 | -13.49 ± 1.529 | -6.89 ± 1.587 |
| Week 8, Hour 19 | -10.13 ± 1.456 | -10.12 ± 1.493 | -9.74 ± 1.388 | -10.78 ± 1.369 | -10.13 ± 1.517 | -5.84 ± 1.587 |
| Week 8, Hour 20 | -10.73 ± 1.454 | -8.06 ± 1.504 | -10.43 ± 1.408 | -10.49 ± 1.369 | -10.47 ± 1.516 | -5.21 ± 1.602 |
| Week 8, Hour 21 | -9.31 ± 1.453 | -7.68 ± 1.489 | -9.66 ± 1.386 | -8.22 ± 1.377 | -10.51 ± 1.514 | -4.12 ± 1.586 |
| Week 8, Hour 22 | -7.90 ± 1.452 | -4.93 ± 1.487 | -5.37 ± 1.385 | -6.35 ± 1.386 | -7.60 ± 1.513 | -1.09 ± 1.585 |
| Week 8, Hour 23 | -4.94 ± 1.475 | -1.93 ± 1.487 | -1.18 ± 1.385 | -2.67 ± 1.377 | -5.54 ± 1.513 | 1.82 ± 1.599 |
| Week 8, Hour 24 | -0.21 ± 1.477 | 1.45 ± 1.501 | 0.29 ± 1.397 | 1.36 ± 1.370 | -2.78 ± 1.529 | 1.98 ± 1.617 |
Trough to peak ratios were derived from an ANCOVA model containing treatment, region, hour, treatment by hour interaction as factors with Baseline as a covariate.
| ratio | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Week 8, Hour 1 | -0.54 ± 1.767 | 0.09 ± 1.859 | -4.51 ± 1.674 | -1.42 ± 1.690 | -5.33 ± 1.863 | 8.23 ± 1.915 |
| Week 8, Hour 2 | -1.59 ± 1.752 | 0.15 ± 1.795 | -3.56 ± 1.685 | -0.57 ± 1.663 | -5.90 ± 1.844 | 6.48 ± 1.913 |
| Week 8, Hour 3 | -2.11 ± 1.781 | -1.53 ± 1.811 | -4.86 ± 1.672 | 0.91 ± 1.649 | -5.89 ± 1.843 | 4.60 ± 1.912 |
| Week 8, Hour 4 | -2.06 ± 1.752 | -1.18 ± 1.794 | -4.15 ± 1.672 | 1.50 ± 1.661 | -5.12 ± 1.859 | 4.68 ± 1.912 |
| Week 8, Hour 5 | -4.29 ± 1.766 | -3.09 ± 1.825 | -3.47 ± 1.671 | -1.70 ± 1.660 | -7.22 ± 1.826 | 2.78 ± 1.912 |
| Week 8, Hour 6 | -4.21 ± 1.751 | -3.12 ± 1.794 | -5.88 ± 1.672 | -1.02 ± 1.648 | -7.91 ± 1.826 | 1.42 ± 1.912 |
| Week 8, Hour 7 | -4.95 ± 1.766 | -2.10 ± 1.794 | -5.40 ± 1.697 | -0.76 ± 1.649 | -8.70 ± 1.826 | 2.25 ± 1.930 |
| Week 8, Hour 8 | -5.28 ± 1.766 | -4.69 ± 1.794 | -5.30 ± 1.684 | -3.02 ± 1.649 | -8.06 ± 1.827 | 3.76 ± 1.950 |
| Week 8, Hour 9 | -3.98 ± 1.766 | -1.59 ± 1.795 | -4.78 ± 1.672 | -1.87 ± 1.649 | -7.46 ± 1.828 | 2.39 ± 1.931 |
| Week 8, Hour 10 | -3.69 ± 1.752 | -0.30 ± 1.794 | -3.40 ± 1.672 | -1.73 ± 1.662 | -7.35 ± 1.828 | 2.54 ± 1.913 |
| Week 8, Hour 11 | -2.47 ± 1.751 | -0.43 ± 1.795 | -4.22 ± 1.672 | -1.74 ± 1.649 | -5.75 ± 1.827 | 3.51 ± 1.913 |
| Week 8, Hour 12 | -5.19 ± 1.752 | 0.73 ± 1.794 | -4.35 ± 1.671 | -3.92 ± 1.650 | -6.25 ± 1.843 | 4.69 ± 1.912 |
| Week 8, Hour 13 | -6.45 ± 1.751 | -2.30 ± 1.794 | -7.25 ± 1.671 | -4.05 ± 1.649 | -8.81 ± 1.826 | 3.20 ± 1.912 |
| Week 8, Hour 14 | -7.37 ± 1.751 | -5.68 ± 1.794 | -9.33 ± 1.671 | -6.12 ± 1.660 | -10.91 ± 1.826 | 0.75 ± 1.912 |
| Week 8, Hour 15 | -10.61 ± 1.752 | -8.28 ± 1.795 | -11.26 ± 1.672 | -9.78 ± 1.661 | -12.04 ± 1.842 | 0.02 ± 1.912 |
| Week 8, Hour 16 | -11.71 ± 1.767 | -10.01 ± 1.797 | -12.63 ± 1.672 | -13.03 ± 1.651 | -16.68 ± 1.843 | -0.33 ± 1.914 |
| Week 8, Hour 17 | -13.71 ± 1.754 | -11.96 ± 1.799 | -15.46 ± 1.685 | -13.72 ± 1.664 | -19.59 ± 1.828 | -3.03 ± 1.933 |
| Week 8, Hour 18 | -14.49 ± 1.756 | -14.37 ± 1.800 | -14.54 ± 1.675 | -15.60 ± 1.664 | -18.55 ± 1.844 | -6.35 ± 1.915 |
| Week 8, Hour 19 | -13.78 ± 1.756 | -13.08 ± 1.801 | -12.85 ± 1.674 | -15.93 ± 1.652 | -15.49 ± 1.830 | -6.98 ± 1.914 |
| Week 8, Hour 20 | -13.92 ± 1.756 | -13.22 ± 1.814 | -12.54 ± 1.699 | -15.47 ± 1.652 | -16.09 ± 1.829 | -6.53 ± 1.934 |
| Week 8, Hour 21 | -14.33 ± 1.754 | -10.06 ± 1.797 | -12.78 ± 1.672 | -13.63 ± 1.662 | -15.34 ± 1.827 | -3.89 ± 1.914 |
| Week 8, Hour 22 | -13.46 ± 1.752 | -8.35 ± 1.794 | -7.52 ± 1.671 | -10.55 ± 1.673 | -12.47 ± 1.826 | -0.94 ± 1.912 |
| Week 8, Hour 23 | -7.88 ± 1.780 | -6.23 ± 1.794 | -5.77 ± 1.671 | -6.73 ± 1.661 | -9.02 ± 1.826 | 2.18 ± 1.930 |
| Week 8, Hour 24 | -3.16 ± 1.781 | -0.64 ± 1.810 | -3.45 ± 1.685 | -3.76 ± 1.651 | -8.90 ± 1.844 | 0.70 ± 1.951 |
Change from baseline was analyzed using plasma aldosterone values measured at Baseline and Week 8.
| picomoles per liter (pmol/L) | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Plasma Aldosterone Levels at Week 8 | -21.5 ± 122 | -20.0 ± 156 | -9.9 ± 266 | -47.5 ± 170 | 277.1 ± 429 | -28.8 ± 163 |
MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from Baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg.
| percentage of participants | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| MSDBP Response | 39.1 | 34.1 | 50.0 | 34.4 | 48.8 | 27.6 |
| MSDBP Control | 32.6 | 29.4 | 41.9 | 29.2 | 45.2 | 18.4 |
MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg.
| percentage of participants | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| MSSBP Response | 39.1 | 37.6 | 48.8 | 34.4 | 52.4 | 17.1 |
| MSSBP Control | 31.5 | 27.1 | 40.7 | 25.0 | 44.0 | 15.8 |
The ACTH stimulation cortisol test was a standard procedure to measure the ability of adrenal cortex to respond to exogenous ACTH and directly assess the adrenal reserve. Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.
| nanomoles per liter (nmol/L) | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo |
|---|---|---|---|---|---|---|
| Core Period: Change From Baseline in Plasma Cortisol Levels by Adrenocorticotropic Hormone (ACTH) Stimulation Test | 729.20 ± 123.753 | 692.74 ± 117.645 | 604.46 ± 125.017 | 609.21 ± 107.923 | 802.32 ± 134.497 | 822.65 ± 116.041 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSDBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSDBP level as a covariate.
| mm Hg | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Withdrawal Period: Change From Week 8 to Week 9 in MSDBP at Week 9, as Measured by OBP | 0.5 ± 0.99 | 0.5 ± 1.08 | 1.6 ± 1.01 | -0.2 ± 1.09 | -0.5 ± 1.03 | 2.5 ± 1.11 | 1.3 ± 1.00 | 1.3 ± 1.02 | -1.2 ± 1.06 | 0.4 ± 1.11 | 1.6 ± 0.83 |
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSSBP was calculated comparing the Week 9 readings to the readings taken at Week 8 (Baseline). The change from Week 8 to week 9 in MSSBP was analyzed using an ANCOVA with treatment and region as factors and Week 8 MSSBP level as a covariate.
| mm Hg | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Withdrawal Period: Change From Week 8 to Week 9 in MSSBP at Week 9 as Measured by OBP | 0.3 ± 1.66 | 3.3 ± 1.80 | 0.5 ± 1.69 | 2.5 ± 1.82 | 0.4 ± 1.72 | 5.3 ± 1.85 | 1.6 ± 1.68 | 4.4 ± 1.69 | -1.5 ± 1.79 | 2.7 ± 1.86 | 1.8 ± 1.39 |
Collected over AEs: From start of the study drug treatment up to 9 weeks; SAE: From signing of the informed consent up to 9 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core Period: LCI699 0.25 mg QD | 0/92 (0%) | 1/92 (1.1%) | 22/92 (23.9%) |
| Core Period: LCI699 0.5 mg QD | 0/87 (0%) | 0/87 (0%) | 22/87 (25.3%) |
| Core Period: LCI699 1.0 mg QD | 0/87 (0%) | 0/87 (0%) | 24/87 (27.6%) |
| Core Period: LCI699 0.5 mg BID | 0/97 (0%) | 0/97 (0%) | 27/97 (27.8%) |
| Core Period: Eplerenone 50 mg BID | 0/84 (0%) | 0/84 (0%) | 26/84 (31%) |
| Core Period: Placebo | 0/76 (0%) | 1/76 (1.3%) | 23/76 (30.3%) |
| Withdrawal Period: LCI699 0.25 mg QD | 0/46 (0%) | 0/46 (0%) | 2/46 (4.3%) |
| Withdrawal Period: LCI699 0.25 mg QD Placebo | 0/38 (0%) | 0/38 (0%) | 1/38 (2.6%) |
| Withdrawal Period: LCI699 0.5 mg QD | 0/44 (0%) | 0/44 (0%) | 1/44 (2.3%) |
| Withdrawal Period: LCI699 0.5 mg QD Placebo | 0/37 (0%) | 0/37 (0%) | 0/37 (0%) |
| Withdrawal Period: LCI699 1.0 mg QD | 0/41 (0%) | 0/41 (0%) | 3/41 (7.3%) |
| Withdrawal Period: LCI699 1.0 mg QD Placebo | 0/37 (0%) | 0/37 (0%) | 5/37 (13.5%) |
| Withdrawal Period: LCI699 0.5 mg BID | 0/45 (0%) | 0/45 (0%) | 4/45 (8.9%) |
| Withdrawal Period: LCI699 0.5 mg BID Placebo | 0/45 (0%) | 0/45 (0%) | 3/45 (6.7%) |
| Withdrawal Period: Eplerenone 50 mg BID | 0/39 (0%) | 0/39 (0%) | 2/39 (5.1%) |
| Withdrawal Period: Eplerenone 50 mg BID Placebo | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Withdrawal Period: Placebo | 0/66 (0%) | 0/66 (0%) | 3/66 (4.5%) |
| Event | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/92 | 0/87 | 0/87 | 0/97 | 0/84 | 1/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| Retinal vein occlusionEye disorders | 1/92 | 0/87 | 0/87 | 0/97 | 0/84 | 0/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| Event | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Withdrawal Period: LCI699 0.25 mg QD | Withdrawal Period: LCI699 0.25 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg QD | Withdrawal Period: LCI699 0.5 mg QD Placebo | Withdrawal Period: LCI699 1.0 mg QD | Withdrawal Period: LCI699 1.0 mg QD Placebo | Withdrawal Period: LCI699 0.5 mg BID | Withdrawal Period: LCI699 0.5 mg BID Placebo | Withdrawal Period: Eplerenone 50 mg BID | Withdrawal Period: Eplerenone 50 mg BID Placebo | Withdrawal Period: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/92 | 4/87 | 1/87 | 2/97 | 3/84 | 10/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 1/37 | 0/45 | 1/45 | 0/39 | 0/36 | 0/66 |
| DizzinessNervous system disorders | 0/92 | 0/87 | 2/87 | 5/97 | 1/84 | 0/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| NasopharyngitisInfections and infestations | 1/92 | 2/87 | 3/87 | 1/97 | 4/84 | 3/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 1/45 | 1/45 | 0/39 | 0/36 | 0/66 |
| Abdominal pain lowerGastrointestinal disorders | 0/92 | 0/87 | 0/87 | 0/97 | 0/84 | 0/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 1/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| Joint sprainInjury, poisoning and procedural complications | 2/92 | 0/87 | 1/87 | 0/97 | 0/84 | 1/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 1/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/92 | 0/87 | 0/87 | 0/97 | 1/84 | 0/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 1/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| SyncopeNervous system disorders | 0/92 | 0/87 | 0/87 | 0/97 | 0/84 | 0/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 1/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| PalpitationsCardiac disorders | 1/92 | 1/87 | 0/87 | 0/97 | 1/84 | 2/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| DiarrhoeaGastrointestinal disorders | 2/92 | 1/87 | 0/87 | 0/97 | 0/84 | 2/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
| NauseaGastrointestinal disorders | 1/92 | 0/87 | 1/87 | 1/97 | 0/84 | 2/76 | 0/46 | 0/38 | 0/44 | 0/37 | 0/41 | 0/37 | 0/45 | 0/45 | 0/39 | 0/36 | 0/66 |
Full Analysis Set (FAS) population included all randomized participants or participants that met the inclusion criteria as described in study documentation protocol excluding misrandomized participants or participants with protocol violations.
| Age, Continuous(years) | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.9 ± 10.5 | 54.8 ± 7.8 | 54.5 ± 9.7 | 54.4 ± 10.8 | 55.3 ± 9.1 | 53.9 ± 8.7 | 54.5 ± 9.50 |
| Sex: Female, Male(Participants) | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 29 | 29 | 31 | 33 | 28 | 31 | 181 |
| Male | 63 | 58 | 55 | 63 | 56 | 46 | 341 |
| Blood Pressure(millimeters of mercury (mm Hg)) | Core Period: LCI699 0.25 mg QD | Core Period: LCI699 0.5 mg QD | Core Period: LCI699 1.0 mg QD | Core Period: LCI699 0.5 mg BID | Core Period: Eplerenone 50 mg BID | Core Period: Placebo | Total |
|---|---|---|---|---|---|---|---|
| Clinic Systolic Blood Pressure (SBP) | 157.72 ± 12.163 | 157.04 ± 11.580 | 159.24 ± 10.415 | 158.50 ± 11.028 | 158.20 ± 10.954 | 156.69 ± 10.121 | 157.93 ± 11.074 |
| Clinic Diastolic Blood pressure (DBP) | 100.43 ± 3.884 | 99.94 ± 3.314 | 100.03 ± 3.580 | 100.21 ± 3.450 | 100.39 ± 3.607 | 100.54 ± 3.814 | 100.25 ± 3.599 |
| 24-hour Ambulatory SBP | 141.97 ± 11.167 | 140.08 ± 13.502 | 143.85 ± 11.613 | 142.20 ± 11.079 | 143.30 ± 13.989 | 142.07 ± 13.150 | 142.25 ± 12.405 |
| 24-hour Ambulatory DBP | 90.13 ± 8.893 | 89.33 ± 8.208 | 91.38 ± 7.998 | 90.81 ± 8.260 | 91.14 ± 8.861 | 90.11 ± 10.439 | 90.49 ± 8.744 |
Ran from Sep 2008 to primary completion in Jul 2009, 9 months.
Results were first posted in Jul 2021, 12 years after primary completion. A results delay was requested in May 2012.
Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat